Neurogene
Builds a single gene therapy for Rett syndrome using a proprietary expression-control platform.
$36.58
After-hours close+0.06 (+0.16%)
At close$36.52(−3.54%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 107.39%Insiders 9.31%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 15.80M · Float 12.54M · 79.3% free float
Institutions13F, as of Mar 31, 2026
101 holders · 16.97M shares · 19 new positions · 63 increased · 17 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 1.72M | 10.87% | 0 | May 15, 2026 |
| Redmile Group, LLC | 1.46M | 9.24% | 0 | May 15, 2026 |
| Casdin Capital, LLC | 1.42M | 8.99% | +125.0K | May 15, 2026 |
| RTW Investments, LP | 1.36M | 8.62% | 0 | May 15, 2026 |
| Ecor1 Capital, LLC | 1.27M | 8.05% | 0 | May 15, 2026 |
| BlackRock, Inc. | 1.01M | 6.36% | +59.5K | May 13, 2026 |
| Baker Bros. Advisors LP | 991.7K | 6.28% | 0 | May 15, 2026 |
| Trails Edge Capital Partners, LP | 782.8K | 4.95% | −2.2K | May 15, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RTW Investments, LP | 9.99% | 1.50M | 13G | Feb 14, 2025 ↗ |
| Redmile Group, LLC | 9.90% | 1.56M | 13G | Feb 17, 2026 ↗ |
| EcoR1 Capital, LLC | 9.90% | 1.44M | 13G | Nov 14, 2025 ↗ |
| Casdin Capital, LLC | 8.70% | 1.30M | 13G | Feb 14, 2025 ↗ |
| Baker Bros. Advisors LP | 7.00% | 991.7K | 13G | Aug 14, 2025 ↗ |
| Eli Casdinincl. Casdin Capital, LLC, Casdin Partners Master Fund, L.P. +1 more | 6.90% | 1.02M | 13G | Nov 8, 2024 ↗ |
| BlackRock, Inc. | 6.80% | 1.01M | 13G | Apr 23, 2025 ↗ |
| FMR LLCincl. Abigail P. Johnson | 5.63% | 731.8K | Nov 12, 2024 ↗ | |
| Capital Master LPincl. Capital LP | 5.40% | 800.0K | 13G | Dec 11, 2024 ↗ |
| Balyasny Asset Management L.P. | 5.18% | 818.7K | 13G | Aug 14, 2026 ↗ |
| Trails Edge Capital Partners, LP | 5.10% | 785.0K | 13G | Dec 15, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Rachel McMinn | director, officer: Chief Executive Officer | 1.34M | 8.51% | Mar 30, 2026 |
| Christine Mikail Cvijic | director, officer: President and CFO | 84.0K | 0.53% | Jul 7, 2026 |
| Stuart Cobb | officer: Chief Scientific Officer | 30.5K | 0.19% | Mar 17, 2026 |
| Julie Jordan | officer: Chief Medical Officer | 12.5K | 0.08% | Mar 30, 2026 |
1 ten-percent owner holds 1.69M shares by Form 4, outside the officers-and-directors figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 7, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale | 4,200 | $36.13 | 84,040 |
| Jul 6, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale | 600 | $36.02 | 88,240 |
| Jul 2, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale · 2 lots | 4,061 | $34.82 | 88,840 |
| Jul 1, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale | 739 | $34.06 | 92,901 |
| May 6, 2026 | Christine Mikail Cvijicdirector, officer: President and CFO | Sale · 2 lots | 9,600 | $31.25 | 93,640 |
| Mar 26, 2026 | Julie Jordanofficer: Chief Medical Officer | Sale | 828 | $21.89 | 12,472 |
| Mar 26, 2026 | Rachel McMinndirector, officer: Chief Executive Officer | Sale | 3,352 | $22.07 | 1,344,307 |
| Mar 26, 2026 | Christine Mikail Cvijicofficer: President and CFO | Sale | 2,558 | $21.62 | 103,240 |
| Mar 13, 2026 | Christine Mikail Cvijicofficer: President and CFO | Sale · 3 lots | 4,045 | $20.81 | 105,798 |
| Mar 13, 2026 | Stuart Cobbofficer: Chief Scientific Officer | Sale · 3 lots | 6,797 | $20.81 | 30,497 |
CongressHouse and Senate disclosures
Not reported.